Vectura's asthma therapy misses primary endpoint in final stage trial : businessinsider

referring to businessinsider

Vectura's asthma therapy misses primary endpoint in final stage trial

Vectura's asthma therapy misses primary endpoint in final stage trial

(Reuters) - Respiratory drug specialist Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a phase III trial carried out by its European partner Mundipharma.Vectura shares were down 10 percent at 124.8 pence at 0706 GMT.They were the biggest losers on the London Stock Exchange on Tuesday.


besides reuters

Vectura's asthma therapy misses primary endpoint in final stage trial

Vectura's asthma therapy misses primary endpoint in final stage trial

Aug 30 Respiratory drug specialist Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a phase III trial carried out by its European partner Mundipharma.Flutiform had not shown "statistically significant" superiority in reducing the yearly rate of the worsening of moderate and severe chronic obstructive pulmonary disease (COPD), when compared to mono-component LABA treatment, Vectura said on Tuesday.Vectura said Mundipharma was currently analysing the trial's other endpoints, but had indicated that the primary endpoint result would prevent it from making a regulatory filing for COPD indication in Europe.


not to mention pharmalive

Lung disease therapy misses primary trial goal

Lung disease therapy misses primary trial goal

Vectura's therapy misses primary goal in late-stage lung disease trialDrugmaker Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a late-stage trial to determine its ability to treat COPD, a type of lung disease, sending the British firm's stock to its lowest in 21 months.Flutiform had not significantly reduced the yearly rate of worsening conditions in patients with moderate and severe chronic obstructive pulmonary disease (COPD), versus mono-component LABA treatment, respiratory drug specialist Vectura said on Tuesday.Vectura said its European license partner Mundipharma, which carried out the study, had indicated that these phase III result would prevent it from making a regulatory filing for COPD indication in Europe.